Call for Abstract

10th World Congress on Stem Cell and Biobanking , will be organized around the theme ““Accelerating Innovative Research & Technology in Stem Cell & Biobanking.””

Stem Cell Convention-2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Stem Cell Convention-2017

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)—but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.
  • Track 1-1Embryonic stem cells
  • Track 1-2Tissue stem cells
  • Track 1-3pluripotent stem cells
  • Track 1-4Neural stem cells
  • Track 1-5Mesenchymal stem cells
  • Track 1-6Skin stem cells
Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases. Stem cells are defined as totipotent progenitor cells capable of self-renewal and multilineage differentiation. Stem cells survive well and show stable division in culture, making them ideal targets for in vitro manipulation. Although early research has focused on hematopoietic stem cells, stem cells have also been recognised in other sites. Research into solid tissue stem cells has not made the same progress as that on hematopoietic stem cells. This is due to the difficulty of reproducing the necessary and precise three dimensional arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. However, the ability of tissue stem cells to integrate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues makes them ideal for cell replacement therapy.
  • Track 2-1Neurodegeneration
  • Track 2-2Malignant and non-malignant diseases
  • Track 2-3Stem cell replacement
  • Track 2-4Allogeneic bone marrow transplantation
  • Track 2-5Oral stem cell therapy
  • Track 2-6Stem cells: therapeutic uses

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions. If researchers can find a reliable way to direct the differentiation of embryonic stem cells, they may be able to use the cells to treat certain diseases. For example, by directing the embryonic stem cells to turn into insulin-producing cells, they may be able to transplant the cells into people with type 1 diabetes.

Other medical conditions that may potentially be treated with embryonic stem cells include:
  • Track 3-1Macular degeneration
  • Track 3-2Human embryonic stem Cells
  • Track 3-3Neural stem cell Therapy
  • Track 3-4Messenchymal stem cell therapy
  • Track 3-5Haematopoietic stem cell transplantation
  • Track 3-6Clinical trials

The cancer stem cell concept has important implications for cancer therapy. If cancer stem cells are responsible for maintaining tumour growth, then eliminating these cells would eventually cure the patient.There is no definitive proof in favour of either theory of cancer growth. However, an increasing amount of evidence suggests that the cancer stem cell theory holds true in some cases. The first evidence in favour of cancer stem cells came from studies of human leukaemia. Researchers found that only a subset of leukaemic cells can cause leukaemia when transplanted into a healthy body, the key characteristic of cancer stem cells.

Since that discovery, many researchers have found cells with cancer stem cell characteristics in a great variety of human and mouse cancers, including breast, brain, skin, prostate and colonic cancers. In some types of tumour the cancer stem cells are rare, for example in colon cancer. In other types of cancer, such as melanoma, a very large number of the tumour cells have cancer stem cell characteristics.

  • Track 4-1Bladder Cancer Stem Cell Markers
  • Track 4-2Medulloblastoma Cancer Stem Cell Markers
  • Track 4-3Lung cancer biomarkers
  • Track 4-4Prostate cancer biomarkers
  • Track 4-5Leukemia Cancer Stem Cell Markers
  • Track 4-6Ovarian Cancer Stem Cell Markers
  • Track 4-7Breast Cancer Stem Cell Markers
Self-renewal and proliferation of stem cell populations is controlled, in part, by induction of apoptosis. The number of stem cells is therefore a balance between those lost to differentiation / apoptosis and those gained through proliferation. Apoptosis of stem cells is believed to be a dynamic process which changes in response to environmental conditions. For example, the release of stem cell factor inhibits apoptosis following spinal cord injury, presumably in an attempt to promote tissue repair. Dysregulation of apoptosis in stem cells is believed to underlie some cancer pathologies, where apoptotic resistance results in uncontrolled growth (i.e. glioblastoma). Controlling apoptosis is also an important focus for studies of stem cell transplantation, where inhibition may increase the survival of grafted cells during replacement therapy. Harnessing the full therapeutic potential of stem cells will require full elucidation of the signal transduction cascades for proliferation, differentiation, and apoptosis.
  • Track 5-1Translational studies for cancer stem cell-based therapies
  • Track 5-2Epigenetics and cancer stem cells
  • Track 5-3Specific cancer immunotherapy
  • Track 5-4Inflammatory diseases and cancer
  • Track 5-5Cancer Stem cells and impaired apoptosis
  • Track 5-6Apoptosis and Haematopoitic Stem cells

Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

  • Track 6-1Vascular tissue engineering and regeneration
  • Track 6-2Organ transplantation and its new techniques
  • Track 6-3Advanced developments in artificial organ system
  • Track 6-4Regenerative-medicine approach
  • Track 6-5Ethics and applications of regenerative medicine
Regeneration means the regrowth of a damaged or missing organ part from the remaining tissue. As adults, humans can regenerate some organs, such as the liver. If part of the liver is lost by disease or injury, the liver grows back to its original size, though not its original shape. And our skin is constantly being renewed and repaired. Unfortunately many other human tissues don’t regenerate, and a goal in regenerative medicine is to find ways to kick-start tissue regeneration in the body, or to engineer replacement tissues.
  • Track 7-1Cell tracking and tissue imaging
  • Track 7-2Hematopoietic stem cells
  • Track 7-3Blastocyst Complementation
  • Track 7-4Decellularization
  • Track 7-53D Bio printing
Cancer stem cells are cells found in tumors that have the ability to propagate the tumor after its dissociation.  In some tumors, this property is expressed by a large fraction of the total tumor cells, meaning abundant cancer stem cells.  However, in many tumors the cancer stem cell fraction is small, mimicking the smaller fractions of stem cells in normal adult tissues.  This distribution of cancer stem cells has captured the imagination of cancer scientists.  There is speculation that cancer stem cells at low fractions in tumors may be responsible for cancer drug resistance, metastasis, and tumor recurrence.
Due to the widely-held importance of cancer stem cells in cancer development and treatment, there is considerable interest in identifying, quantifying, and investigating them.  However, because of the inherent heterogeneity of human tumor cellularity, the search for cancer stem cell specific biomarkers has been even more fraught with false positives than the search for specific biomarkers for normal tissue stem cells.
  • Track 8-1Cancer Stem Cell BioMarkers
  • Track 8-2Trophoblast Stem Cell BioMarkers
  • Track 8-3Cardiac Stem Cell Biomarkers
  • Track 8-4Hematopoietic Stem Cell Biomarkers
  • Track 8-5Skin Stem Cell Markers
  • Track 8-6Retinal Stem Cell Markers
  • Track 9-1Invivo Stem cell Microenvironment
  • Track 9-2Invitro Stem Cell Microenvironment
  • Track 9-3Vertebrate Adult Stem cell Niche
  • Track 9-4Cancer Stem Cell Niche
  • Track 9-5Extracellular Matrix Mimicking strategies for Stem cell Niche
  • Track 10-1Prosthodontics and Endodontics
  • Track 10-2Periodontal therapy/surgery
  • Track 10-3Effects of guided tissue regeneration
  • Track 10-4Advancements in biomedical and tissue engineering techniques
Biobanks play a crucial role in biomedical research. The wide array of bio specimens (including blood, saliva, plasma, and purified DNA) maintained in biobanks can be described as libraries of the human organism. They are carefully characterized to determine the general and unique features of the continuous cell line and the absence or presence of contaminants, therefore establishing a fundamental understanding about the raw material from which the biological product is being derived and maintained. Biobanks catalog specimens using genetic and other traits, such as age, gender, blood type, and ethnicity. Some samples are also categorized according to environmental factors, such as whether the donor had been exposed to radiation, asbestos, or some other substance that can affect human genes.
  • Track 11-1Virtual Biobanks 
  • Track 11-2Tissue Banks 
  • Track 11-3Hematopoietic stem cell bank
  • Track 11-4Umbilical cord blood banks
  • Track 11-5Ethical and legal Issues
Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer affects reproductive health and preservation options are growing, sparked in part by the increase in the survival rate of cancer patients. The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos after in vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.
ART World Congress Symposium on Safe and Efficient IVF New York City, USA, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida, USA, World Conference on Regenerative Medicine 2015 Leipzig, Germany, ESBB conference Johannesburg, South Africa, World Conference on Regenerative Medicine 2015 Leipzig Germany, Keystone Stem Cells and Regeneration in the Digestive Organs (X6) Keystone, Colorado, USA, Molecular and Cellular Basis of Growth and Regeneration (A3) Breckenridge, Colorado, USA, Keystone Cardiac Development, Regeneration and Repair (Z2) Snowbird, Utah, USA, Tissue Niches & Resident Stem Cells in Adult Epithelia Gordon Research Conference Hong Kong, China.
  • Track 12-1New advances in male fertility preservation
  • Track 12-2Embryo, Sperm, Oocyte Storage
  • Track 12-3Fertility, tissue and organ preservation
  • Track 12-4In vitro Fertilization (IVF) Therapy
  • Track 12-5Fertility Biobank for Future Research
Ethical issues are commonly present in many aspects of Biobanking. The fact that Biobanks deal with human samples, invading an individual autonomy or limiting self-control, provokes a number of ethical issues. Who is actually competent to give informed consent and donate a sample? When individuals donate part of their body to a biobank, how is that human sample processed? Who is the owner of the sample? Who should decide how it should be used? Who has the right to know individual results of research? These and many more ethical dilemmas exist in the ethical framework of biobanks. With the recent rapid developments in Biobanking, all of these issues are magnified with plenty of further new questions continuously arising. Ethical framework has been the most controversial issue in the domain of biobanking. Thus, it is not surprising that there is a substantial literature focusing on ethical dilemmas in biobanking, such as informed consent, privacy, protection, and returning of results to participants. For many years, researchers at CRB have provided constructive advice on how to deal with ethical aspects of research using human tissue material and personal data. For more than 80 years tissue has been derived from human bodies, stored, distributed and used for therapeutic, educational, forensic and research purposes as part of healthcare routine in most western countries.
American Society for Bioethics and Humanities Houston, USA, Association of Bioethics World Congress Edinburgh, UK, Oxford Global Health and Bioethics International Conference Oxford shire, UK, CFP: Global Forum on Bioethics in Research Foundation Merieux, France, Hands On Biobanks 2016 conference Vienna, Austria, Global Biobanking London, UK, The Biomarker Conference Orlando, Florida – USA, ART World Congress Symposium on Safe and Efficient IVF New York City, United States, VIII International Postharvest Symposium: Enhancing Supply Chain and Consumer Benefits - Ethical and Technological Issues Cartagena, Murcia, Spain.
  • Track 13-1Ownership, Property Rights and Commercialization in Relation to Biobanking
  • Track 13-2Ethical considerations surrounding biobanking and biorepository operation.
  • Track 13-3Legal and Ethical Framework For Collaborative Biobanking Across Europe
  • Track 13-4Factors Influencing Biobanks Prices
  • Track 13-5Ethical issues & future use of samples
  • Track 13-6Related Conference of Biobank Et
Biorepositories provide a resource for researchers to increase understanding of complex diseases. Studies such as the Lung Genomics Research Consortium (LGRC), a two-year project launched in October 2009, are going a step further than standard biobanking practices and characterizing the samples with their molecular makeup. The molecular data can then be mined along with the clinical data. Led by National Jewish Health and funded by the National Heart, Lung and Blood Institute, a division of the National Institutes of Health (NIH), the LGRC project consists of five institutions, including Dana-Farber Cancer Institute. Collaborators in the project work with samples banked at the Lung Tissue Research Consortium (LTRC), which houses tissue samples and blood from lung disease sufferers, primarily chronic obstructive pulmonary disease (COPD), along with a rich set of clinical data from patients
Immuno-Oncology London UK, Next-Generation Cancer Immunotherapies San Diego, USA, ESBB conference Johannesburg, South Africa, HandsOn Biobanks 2016 conference Vienna, Austria, American Society for Bioethics and Humanities Houston, USA, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, ISSCR Pluripotency: From basic science to therapeutic applications Kyoto, Japan, Craniofacial Morphogenesis & Tissue Regeneration Ventura, CA, USA, Phacilitate Cell & Gene Therapy World Washington D.C., USA, Notch Signaling in Development, Regeneration & Disease Gordon Research Conference Lewiston, ME, USA.
The biobanking market is poised for explosive growth if it can overcome the challenges of an adolescent industry. According to an August 2012 Infiniti Research report titled “Global Biobanking Market 2011-2015,” the biobanking market will increase 30 per cent from 2011 to 2015 to nearly $183 billion. Growth is being driven by an increase in population genetics studies, personalized medicine, and the use of genetic information in food safety, forensics, and disease surveillance.
  • Track 14-1Identification of useful biomarkers
  • Track 14-2New challenges confronting the preservation sciences
  • Track 14-3Challenges and latest strategies for successful samples collection.
  • Track 14-4Pathology databanking and biobanking
The global biopreservation market is expected to reach USD 3,731.03 Million by 2020 from USD 2,150.48 Million in 2015, growing at a CAGR of 11.65% between 2015 and 2020. Biopreservation is used to ensure the stability, quality and purity of biospecimens. With a CAGR of 23.7%, global market value for cryopreservation equipment used in stem cells industry is anticipated to worth US$2.2 billion by 2015. On a global scale, North America accounts for nearly 35% of the market and will likely witness a higher growth rate in the upcoming years, in comparison with Asia-Pacific. While US accounts for the highest share of the global market value on a country basis, India and China surpasses the US in terms of growth rate anticipated in the near future. As per our analysis, freezers represent more than half of the cryopreservation equipment market value while Cyropreservative reagents stand for a share of close to 20%. The global biopreservation market is poised for rapid growth between 2015 and 2020. The drivers include increasing healthcare expenditure, growing demand for preserving new-born’s stem cells, increasing R&D spending on research, and increasing adoption of regenerative medicine.
  • Track 15-1Global biobanks market in USA
  • Track 15-2Biobanking for Medicine in Europe
  • Track 15-3Stem cell market in south Africa
  • Track 15-4Cryogenic Storage systems in Australia
  • Track 15-5Biopreservation Market in Asia
  • Track 15-6Biobanking financing and Biobanking investment